RBMY2OP

Across TCGA pan-cancer cohorts, RBMY2OP RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated RBMY2OP data layer.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RBMY2OP RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMY2OP expression acts as an unfavorable survival marker.

LUSC, KIRP, and UCEC are the cancer types where RBMY2OP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Tertile	All	0.184	0.665	<.001	144	view →
KIRP	OS	Tertile	All	0.580	0.903	<.001	72	view →
UCEC	OS	Tertile	II,III,IV	0.198	0.768	.002	72	view →
LIHC	OS	Tertile	II,III,IV	0.057	0.724	<.001	72	view →
LUAD	OS	Tertile	III,IV	0.057	0.680	<.001	36	view →
MESO	OS	Tertile	All	0.018	0.559	<.001	18	view →
BRCA	DFS	Tertile	II,III,IV	0.321	0.889	<.001	18	view →
STAD	OS	Tertile	All	0.460	0.733	.016	18	view →
BLCA	OS	Tertile	IV	0.132	0.599	.004	18	view →
THCA	DFS	Tertile	All	0.184	0.814	.023	9	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

RBMY2OP–LUSC (DFS)

Open the LUSC breakdown →